These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19941237)

  • 41. [Managing Graves' orbitopathy].
    Kahaly GJ
    Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():63-6. PubMed ID: 15255315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis and management of thyroid orbitopathy.
    Rose JG; Burkat CN; Boxrud CA
    Otolaryngol Clin North Am; 2005 Oct; 38(5):1043-74. PubMed ID: 16214573
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment of difficult endocrine orbitopathy cases].
    Breuer T; Ammann-Rauch D; Tasman AJ
    Laryngorhinootologie; 2007 May; 86(5):376-81. PubMed ID: 17252323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transcaruncular orbital decompression: an alternative procedure for graves ophthalmopathy with compressive optic neuropathy.
    Bernardino CR; Chang EL; Rubin PA
    Am J Ophthalmol; 2006 Oct; 142(4):711-2; author reply 712-3. PubMed ID: 17011891
    [No Abstract]   [Full Text] [Related]  

  • 45. Graves' orbitopathy.
    Bhatnagar A; Tsirbas A; Douglas RS; Goldberg RA; Hoyama E
    Ophthalmology; 2007 Feb; 114(2):392.e1-2. PubMed ID: 17270688
    [No Abstract]   [Full Text] [Related]  

  • 46. Late orbital radiotherapy combined with intravenous methylprednisolone in the management of long-lasting active graves' orbitopathy: a case report and literature review.
    Verrienti M; Gagliardi I; Valente L; Stefanelli A; Borgatti L; Franco E; Galiè M; Bondanelli M; Zatelli MC; Ambrosio MR
    Endocrine; 2024 Aug; 85(2):576-583. PubMed ID: 38517640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.
    Yu Y; Hu YX; Lu MX; Ouyang ZL; Xu MT; Zhao LY; Wang M
    Ophthalmol Ther; 2024 Apr; 13(4):1015-1024. PubMed ID: 38376797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical perspectives of thyroid eye disease.
    Durairaj VD
    Am J Med; 2006 Dec; 119(12):1027-8. PubMed ID: 17145242
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Viral conjunctivitis interfering with the clinical activity score and management of thyroid ophthalmopathy.
    Boboridis KG; Konstas AG; Krassas GE; Georgiadis NS
    Orbit; 2006 Mar; 25(1):27-9. PubMed ID: 16527772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of management of Graves' disease in District General Hospital: achievement of consensus guidelines.
    Dasgupta S; Savage MW
    Int J Clin Pract; 2005 Sep; 59(9):1097-100. PubMed ID: 16115188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statins in Graves Orbitopathy: A New Therapeutic Tool.
    Lanzolla G; Comi S; Cosentino G; Pakdel F; Marinò M
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S29-S39. PubMed ID: 38054983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thyroid dysfunction: managing the ocular complications of Graves' disease.
    Fries PD
    Geriatrics; 1992 Feb; 47(2):58-60, 63-4, 70. PubMed ID: 1735520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of rituximab in treating steroid-resistant Graves' orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China.
    Zhang Z; Feng X; Guo Y; Kang X; Wang D; Zhang J; Zeng Z; Yuan G
    Heliyon; 2024 Jun; 10(11):e31932. PubMed ID: 38867959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Timing of surgery for Graves' orbitopathy.
    Meyer DR
    Ophthalmology; 2007 Feb; 114(2):393; author reply 393.e1-2. PubMed ID: 17270689
    [No Abstract]   [Full Text] [Related]  

  • 55. [Graves' orbitopathy: Current concepts for medical treatment].
    Oeverhaus M; Stöhr M; Möller L; Führer D; Eckstein A
    Laryngorhinootologie; 2023 Mar; 102(3):177-185. PubMed ID: 36858060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapy for Graves' ophthalmopathy].
    Zheng J; Zhang X; Gong R; Wang J; Tan T
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Oct; 21(5):876-9. PubMed ID: 15553880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Graves' ophthalmopathy: state of the art and perspectives.
    Bartalena L; Wiersinga WM; Pinchera A
    J Endocrinol Invest; 2004 Mar; 27(3):295-301. PubMed ID: 15165007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Full-thickeness anterior blepharotomy and transpalpebral fat decompression in Graves' orbitopathy.
    Iveković R; Novak-Laus K; Tedeschi-Reiner E; Masnec-Paskvalin S; Sarić D; Mandić Z
    Coll Antropol; 2005; 29 Suppl 1():33-6. PubMed ID: 16193673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical or surgical decompression of optic neuropathy in Graves' ophthalmopathy: the choice remains unclear.
    Kapamajian MA
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):132. PubMed ID: 16817832
    [No Abstract]   [Full Text] [Related]  

  • 60. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
    Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
    Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.